| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Completed Research
Forum: FightAIDS@Home
Thread: Interesting news articles about AIDS |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 1122
|
|
| Author |
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Scientists find HIV's 'missing link' in sick chimps
 Scanning electron microscope image of an HIV particle. The simian version of the virus causes a much milder infection in apes and monkeys. Scientists believe they have found a "missing link" in the evolution of the virus that causes Aids. It bridges the gap between an infection that does no harm to most non-human primates and one that kills millions of people...... |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
96-Week MERIT ES Analysis Shows Efficacy Of P...ent With 48-Week Analysis
At 96-week follow up, data from the MERIT ES analysis show that treatment-naïve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir® (zidovudine/lamivudine) experienced comparable virologic suppression to undetectable levels and significantly greater increases in CD4 T-cell count through 96-weeks, compared to patients taking efavirenz in combination with zidovudine/ lamivudine. The data also show the favorable tolerability of Celsentri/Selzentry, which was associated with fewer discontinuations due to adverse events.1 The 96-week results from MERIT ES were presented today at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa. MERIT ES is an analysis of the data from the MERIT (Maraviroc versus Efavirenz Regimens as Initial Therapy) study following retesting of screening samples using the enhanced sensitivity Trofile™ assay - therefore representing a subset of the MERIT primary analysis population. This enhanced sensitivity test was not available at the time of the MERIT study and is the only version of Trofile currently available..... |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
New HIV strain leapt to humans from gorillas: Study
Paris: French virologists said they had found a new subtype of the AIDS virus that appears to have jumped the species barrier to humans from gorillas. The new strain, found in a woman from Cameroon, West Africa, is part of the HIV-1 family of microbes that account for the vast majority of cases of human immunodeficiency virus (HIV), they said. Until now, all have been linked to the chimpanzee. The new subtype has been called P, adding to three established HIV-1 subtypes -- M, by far the most prevalent, and O and N, which are rare..... |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
New Strain of H.I.V. Is Discovered :
----------------------------------------http://www.nytimes.com/2009/08/05/science/05hiv.html?hpw New Antiretroviral Drug Effective as First HIV Treatment: http://www.medpagetoday.com/HIVAIDS/HIVAIDS/15361 [Edit 1 times, last edit by Former Member at Aug 5, 2009 4:59:19 PM] |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
|
||
|
|
nasher
Veteran Cruncher USA Joined: Dec 2, 2005 Post Count: 1423 Status: Offline Project Badges: 
|
New HIV strain leapt to humans from gorillas: Study Paris: French virologists said they had found a new subtype of the AIDS virus that appears to have jumped the species barrier to humans from gorillas. The new strain, found in a woman from Cameroon, West Africa, is part of the HIV-1 family of microbes that account for the vast majority of cases of human immunodeficiency virus (HIV), they said. Until now, all have been linked to the chimpanzee. The new subtype has been called P, adding to three established HIV-1 subtypes -- M, by far the most prevalent, and O and N, which are rare..... wow and we havent goten the first one cured yet... oh well line up the computers and lets get them all knocked out while hopefully we find ways to limiting the spread of AIDS.  |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Now, an HIV blocking gel for women
Scientists have developed a "molecular condom", which they claim is actually a vaginal gel that would help protect women from contracting the deadly HIV during sexual intercourse..... |
||
|
|
nasher
Veteran Cruncher USA Joined: Dec 2, 2005 Post Count: 1423 Status: Offline Project Badges:
|
Now, an HIV blocking gel for women Scientists have developed a "molecular condom", which they claim is actually a vaginal gel that would help protect women from contracting the deadly HIV during sexual intercourse..... this last one worries me... first it says it help protect women (how about men?) second how many people will believe 100% effective i dont need to worry... third is it a condom too or just HIV protection... fourth i think this will give people a false sense of saftey. |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Synthetic Protein Thwarts HIV Infection in Lab:
http://health.msn.com/health-topics/cold-and-...x?cp-documentid=100243588 Researchers Decode HIV Genome: http://www.voanews.com/english/2009-08-06-voa38.cfm |
||
|
|
Dan60
Senior Cruncher Brazil Joined: Mar 29, 2006 Post Count: 185 Status: Offline Project Badges: 
|
PRO 140
PRO 140 is a humanized monoclonal antibody developed by Progenics' scientists, designed to block HIV infection by inhibiting the virus' ability to bind to and enter immune system cells. As a monoclonal antibody PRO 140 is not expected to be metabolized by the liver and, as such, has the potential for a better tolerability profile than many approved therapies for HIV infection. Unlike small-molecule CCR5 antagonists, PRO 140 inhibits HIV entry at concentrations that in vitro do not appear to block CCR5's natural activity of directing the migration of immune cells towards sites of inflammation in the body. PRO 140 was given "Fast Track" designation by FDA, a formal process which facilitates development and expedites regulatory review of drugs intended to address unmet medical needs for serious or life-threatening conditions.  How PRO 140 works PRO 140 prevents HIV from entering healthy immune system cells by binding to a distinct site on the cellular co-receptor CCR5; one of two receptors required for HIV entry into susceptible cells -- the other is the T-Cell CD4. CCR5's role in HIV infection was characterized by Progenics and its collaborators in 1996.1 (Some strains of HIV use the CXCR4 co-receptor as a portal of entry either exclusively or alternatively with CCR5 and are therefore not inhibited by PRO 140). Through its surface glycoprotein 120 ("GP120"), HIV first binds to CD4, and then binds to either the CCR5 or CXCR4 co-receptor, thus enabling conformational changes that permit fusion of the virus with the cell membrane, and facilitate entry of the viral genetic information into the cell and subsequent viral replication. By binding to CCR5 first, PRO 140 blocks HIV from binding to CCR5 and fusing with the cell membrane, thereby inhibiting the viral replication process. 1 Dragic, et al. Nature. 381, 667-673 (1996) http://www.progenics.com/prod_pro140.cfm PRO 140 is currently in phase 2 clinical testing for the treatment of HIV infection. |
||
|
|
|